<DOC>
	<DOC>NCT02674854</DOC>
	<brief_summary>To evaluate ocular hypotensive efficacy and safety of PG324 Ophthalmic Solution compared to netarsudil (AR-13324) ophthalmic solution 0.02% and latanoprost ophthalmic solution 0.005%</brief_summary>
	<brief_title>Double-masked Study of PG324 Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma, Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Latanoprost</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>1. 18 years of age or older (19 years of age or older in Canada) 2. Diagnosis of open angle glaucoma or ocular hypertension in both eyes 3. Unmedicated intraocular pressure &gt;20mmHg and &lt;36mmHg in both eyes at 2 qualification visits 4. Corrected visual acuity equivalent to 20/200 5. Able to give informed consent and follow study instructions 1. Clinically significant ocular disease 2. Pseudoexfoliation or pigment dispersion component glaucoma, history of angle closure or narrow angles 3. Unmedicated intraocular pressure ≥36mmHg 4. Use of more than 2 ocular hypotensive medications within 30 days of screening 5. Known hypersensitivity to any component of the formulation 6. Previous glaucoma surgery or refractive surgery 7. Ocular trauma within 6 months prior to screening 8. Any ocular surgery or nonrefractive laser treatment within 3 months prior to screening 9. Recent or current ocular infection or inflammation in either eye 10. Used ocular medication in either eye of any kind within 30 days of screening 11. Mean central corneal thickness &gt;620µm at screening 12. Any abnormality preventing reliable applanation tonometry of either eye 13. Clinically significant abnormalities in lab tests at screening 14. Clinically significant systemic disease 15. Participation in any investigational study within 30 days prior to screening 16. Used any systemic medication that could have a substantial effect on intraocular pressure within 30 days prior to screening 17. Women who are pregnant, nursing, planning a pregnancy or not using a medically acceptable form of birth control</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>